Rabinowitz Matthew sold $196K of NTRA

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 731 shares of Natera, Inc. (NTRA) at $267.99 ($0.20M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Aug 6, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale of 731 shares at $267.9893 on 2026-08-03, with the filing made on 2026-08-05, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but the 10b5-1 designation generally limits actionable signal for valuation or near-term catalysts.

03

What to watch

The article provides only the sale details and post-transaction holdings; it does not include any concurrent buy activity, guidance changes, or operational updates.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-05 for a sale dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA) by executive chairman Matthew Rabinowitz.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera executive chairman Matthew Rabinowitz sold 731 shares in an open-market transaction for about $195.9K, disclosed via Form 4.

Expected impact

Likely minimal impact on NTRA price; any effect would be short-lived unless accompanied by other company-specific news.

Evidence & confidence

The filing is a routine Form 4 insider transaction and explicitly notes a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, some traders may view insider selling as a mild negative sentiment input, especially if paired with other negative signals not present here.

Key entities

  • Natera, Inc.

    Company whose executive chairman insider sale is disclosed on Form 4.

  • Matthew Rabinowitz

    Executive chairman and reporting person who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.